Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
25 sept. 2024 09h15 HE | Cyclacel
Cyclacel announces completion of enrollment in the biomarker-enriched cohort of its Phase 2 study - Patients are preselected for C
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19 mars 2024 16h05 HE | Cyclacel
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
13 mars 2024 16h05 HE | Cyclacel
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals logo
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
30 nov. 2023 09h15 HE | Cyclacel
Cyclacel regains compliance with Nasdaq listing rule after filing Form-10Q for the quarter ended September 30, 2023
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
30 déc. 2020 07h00 HE | Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...